Osteoarthritis (OA) is a degenerative joint condition characterised by progressive cartilage loss and chronic inflammation, resulting in pain, stiffness, and reduced mobility. Existing treatments, such as painkillers and steroid injections, provide only temporary relief, while knee replacement surgery is expensive, invasive, and involves a prolonged recovery period. These limitations significantly impact patients’ quality of life, especially among low-income individuals who face limited access to advanced and affordable treatment options.

The project offers a regenerative, minimally invasive solution through the use of Platelet-derived Extracellular Vesicles (PEVs). These vesicles contain bioactive molecules that stimulate cartilage repair and regeneration, while also modulating inflammation by balancing pro- and anti-inflammatory cytokines. Unlike conventional treatments that only mask symptoms, PEVs promote long-term joint preservation and improved joint function by enhancing lubrication and mobility. Administered via injection, this therapy provides a non-surgical, cost-effective alternative.

The innovation lies in the development and application of Platelet-derived Extracellular Vesicles (PEVs) as a regenerative therapy for osteoarthritis. Unlike conventional treatments, PEVs harness the body’s own biological components—specifically healing factors from activated platelets—to stimulate cartilage regeneration, modulate inflammation, and restore joint function. This approach offers a novel, minimally invasive alternative to surgery. Additionally, the introduction of an allogeneic PEV product (Product 2) represents a significant advancement, enabling scalable production and wider accessibility, particularly for patients who may not be suitable for or have access to autologous treatments.